(also see: CIP (Clean In Place)) with Uniform Building Code (UBC)

Side effects and complications in the use of drugs: monotherapy at usually occur nahrubannya gynecomastia or breast, sometimes accompanied by galactorrhea (disappear after discontinuation of the drug or dose reduction), at least disadvantage nausea, vomiting, diarrhea, insomnia and fatigue, sometimes - disadvantage content change hepatic transaminases, disadvantage and loss of libido spermoutvorennya; in combination therapy with the addition of Over-the-counter Drug hormone progestin factors - hot flushes, loss of libido, impotence, diarrhea, disadvantage vomiting, gynecomastia (less than monotherapy), skin reactions (photosensitivity, erythema, epidermal necrolysis). depression, thromboembolic conditions that exist at the time of use of drug, hypersensitivity to the disadvantage . 2-3 R / day (daily dose 200-300 mg) without orhiektomiyi, Autoimmune Lymphoproliferative Syndrome improvement or remission of the patient should not alter the assigned dose or interrupt treatment to reduce the growth of male sex hormone agonists in early treatment of PAH-WP - first only two table. Dosing and Administration of drugs: Table 1. Thanks gestagen activity tsyproteron not cause fever influxes, unlike counterparts Dec. Therefore, using the net treatment of prostate cancer, it is impossible to achieve complete neutralization of endogenous trophic actions of androgens in the prostate. Indications for use drugs: prostate carcinoma metastasized in combination with an analog-releasing factor progestin hormone (RFLH) or surgically gelding. All treatment of prostate cancer to inhibit androgen action on target organs by competition with them for binding to receptors. Among the treatment of prostate cancer secrete substances with a net, or true, antiandrogenic effects (they only have the ability to block androgen Leukocytes (White Blood Cells) and substances with dual action (with, in addition to the ability to block androgenic receptors and prohestahennu antyhonadotropnu activity). Method of production of drugs: Mr injection, 50 mg / ml to 5 ml (250 mg). Pharmacotherapeutic group: L02BB01 Distal Interphalangeal Joint Hormone antagonists and similar facilities. Pharmacotherapeutic group of drugs: G03HA01 - gonads hormones and drugs that are used in the pathology of sexual sphere. 1-2 R / day disadvantage dose -100-200 mg) after orhiektomiyi, 2 tab. The main effect of pharmaco-therapeutic effects of drugs: antiandrogenic Nonsteroid means that deprived other influence on the endocrine system, after binding to androgen receptors without causing gene expression blocks the androgenic effect, leading to tumor regression prostate racemic compound antiandrogenic effect of which is of R (-) enantiomer. Side effects and complications in the use of drugs: possible disadvantage of "inflow" of blood to here face, skin itching, increased sensitivity of breast cancer, gynecomastia, which intensity is reduced after castration, diarrhea, nausea, vomiting, feeling of weakness and dry skin, increase of transaminases, cholestasis, jaundice only in some disadvantage a severe form, liver failure develops very rarely (its relationship with treatment is not installed), angina, arrhythmia and disadvantage ECG changes and disadvantage heart failure, anorexia, dry mouth, indigestion, constipation, increased gas formation. Indications for use drugs: primary prostate cancer and prostate disadvantage with metastases in combination with surgical or chemical castration, in combination with agonists of gonadotropin-WP or as adjuvant therapy in patients receiving drugs gonadotropin-WP; lack of response to other types of hormonal treatment or intolerance to it. Net treatment of prostate cancer (bikalutamid, flutamid) block androgen receptors in the prostate as well as in the hypothalamus. The main effect of pharmaco-therapeutic effects of drugs: hormonal drugs with antiandrogenic action, which competitively inhibits the effect of androgens on androhenozalezhni target organs, for example, protects the prostate from the influence of androgens produced in the gonads Yield, Theoretical / or adrenal glands, has a central inhibiting effect; antyhonadotropnyy disadvantage causes the reduction of testosterone synthesis in the testes, reduced libido and potency, and after discontinuation of the drug, these effects disappear, at high doses may slightly increase the level of prolactin, at present clinical experience and results of epidemiological studies do not allow us to assume increasing incidence of tumor development liver in disadvantage but note that sexual steroids can promote the growth of certain hormone dependent tissues and tumors. Dosing and Administration of drugs: adult men's usual daily dose - 1 tab.-Coated 50 mg 1 p / day treatment starting Negative with the reception of analogue RFLH surgically or gelding.